Industry Hails Access Implications As FTC Promises PBM Probe
Follows AAM And Biosimilars Forum’s Calls For Action Over Behaviors That Restrict Access
The US FTC’s announcement of an inquiry into PBMs will be music to the ears of the country’s generics and biosimilars industry, which has long called for action on abusive practices that undermine access.
You may also be interested in...
As the dust settles after a wave of fresh adalimumab biosimilar launches, the US Biosimilars Forum’s executive director Julie Reed talks to Generics Bulletin about how other stakeholders need to step up to meet industry’s commitment to the sector – as well as how PBMs are distorting the market and streamlined regulation is needed to drive competition.
California is set to begin producing its own biosimilar insulin products, having been designated $100m by state governor Gavin Newsom to complete the project.
Senators Maria Cantwell and Chuck Grassley have introduced a bill which would limit pharmacy benefit managers’ ability to engage in “unfair and deceptive” business practices, a move which has been welcomed by the Biosimilars Forum.